Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.

Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML.

Cell. 2019 Aug 8;178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. Epub 2019 Jul 18.

PMID:
31327527
2.

A half century of change in diagnostic neuropathology: from the giants of yore to current brain tumor classification.

Louis DN.

Hum Pathol. 2019 Jul 11. pii: S0046-8177(19)30124-8. doi: 10.1016/j.humpath.2019.06.006. [Epub ahead of print]

PMID:
31302204
3.

Data Sets for the Reporting of Tumors of the Central Nervous System.

Louis DN, Wesseling P, Brandner S, Brat DJ, Ellison DW, Giangaspero F, Hattab EM, Hawkins C, Judge MJ, Kleinschmidt-DeMasters B, Komori T, McLean C, Paulus W, Perry A, Reifenberger G, Weller M, Rous B.

Arch Pathol Lab Med. 2019 Jun 20. doi: 10.5858/arpa.2018-0565-OA. [Epub ahead of print]

PMID:
31219344
4.

cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates.

Louis DN, Ellison DW, Brat DJ, Aldape K, Capper D, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, von Deimling A, Wesseling P.

Brain Pathol. 2019 Jul;29(4):469-472. doi: 10.1111/bpa.12732. Epub 2019 May 22. Review.

PMID:
31038238
5.

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.

Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS.

Acta Neuropathol Commun. 2019 Apr 29;7(1):66. doi: 10.1186/s40478-019-0720-8.

6.

Characterization of applicants for residency training in pathology: Does diversity exist?

Mortensen SJ, Menard EJ, Olson EB, Deng HC, Hasserjian R, Black-Schaffer WS, Pappadia T, Louis DN, Nazarian RM.

Ann Diagn Pathol. 2019 Jun;40:23-25. doi: 10.1016/j.anndiagpath.2019.02.010. Epub 2019 Feb 10.

PMID:
30852247
7.

cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation.

Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G, Louis DN.

Acta Neuropathol. 2019 Apr;137(4):683-687. doi: 10.1007/s00401-019-01987-0. Epub 2019 Mar 8. No abstract available.

PMID:
30848347
8.

The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma.

Fritchie K, Jensch K, Moskalev EA, Caron A, Jenkins S, Link M, Brown PD, Rodriguez FJ, Guajardo A, Brat D, Velázquez Vega JE, Perry A, Wu A, Raleigh DR, Santagata S, Louis DN, Brastianos PK, Kaplan A, Alexander BM, Rossi S, Ferrarese F, Haller F, Giannini C.

Acta Neuropathol. 2019 Feb;137(2):307-319. doi: 10.1007/s00401-018-1952-6. Epub 2018 Dec 24.

9.

Implementing the DICOM Standard for Digital Pathology.

Herrmann MD, Clunie DA, Fedorov A, Doyle SW, Pieper S, Klepeis V, Le LP, Mutter GL, Milstone DS, Schultz TJ, Kikinis R, Kotecha GK, Hwang DH, Andriole KP, Iafrate AJ, Brink JA, Boland GW, Dreyer KJ, Michalski M, Golden JA, Louis DN, Lennerz JK.

J Pathol Inform. 2018 Nov 2;9:37. doi: 10.4103/jpi.jpi_42_18. eCollection 2018.

10.

Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.

Bale TA, Jordan JT, Rapalino O, Ramamurthy N, Jessop N, DeWitt JC, Nardi V, Alvarez MM, Frosch M, Batchelor TT, Louis DN, Iafrate AJ, Cahill DP, Lennerz JK.

Neuro Oncol. 2019 May 6;21(5):596-605. doi: 10.1093/neuonc/noy201.

PMID:
30496526
11.

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".

Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M.

Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26. No abstract available.

PMID:
30259105
12.

Localized crystal-storing histiocytosis of the posterior fossa.

Flanagan ME, Keene CD, Louis DN, Juric-Sekhar G.

Neuropathology. 2018 Oct;38(5):529-534. doi: 10.1111/neup.12486. Epub 2018 Jul 31.

13.

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A.

Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.

PMID:
29687258
14.

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.

Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popović M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE, Suvà ML.

Science. 2018 Apr 20;360(6386):331-335. doi: 10.1126/science.aao4750.

15.

A feast of reviews about brain and pituitary tumor pathology.

Louis DN.

Brain Tumor Pathol. 2018 Apr;35(2):49-50. doi: 10.1007/s10014-018-0315-2. No abstract available.

PMID:
29666968
16.

Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.

von Deimling A, Ono T, Shirahata M, Louis DN.

Semin Neurol. 2018 Feb;38(1):19-23. doi: 10.1055/s-0038-1636430. Epub 2018 Mar 16. Review.

PMID:
29548048
17.

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.

Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P.

Acta Neuropathol. 2018 Apr;135(4):639-642. doi: 10.1007/s00401-018-1826-y. Epub 2018 Mar 1. No abstract available.

PMID:
29497819
18.

A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle.

Goode B, Mondal G, Hyun M, Ruiz DG, Lin YH, Van Ziffle J, Joseph NM, Onodera C, Talevich E, Grenert JP, Hewedi IH, Snuderl M, Brat DJ, Kleinschmidt-DeMasters BK, Rodriguez FJ, Louis DN, Yong WH, Lopes MB, Rosenblum MK, Butowski N, Tihan T, Bollen AW, Phillips JJ, Wiita AP, Yeh I, Jacobson MP, Bastian BC, Perry A, Solomon DA.

Nat Commun. 2018 Feb 23;9(1):810. doi: 10.1038/s41467-018-02826-8.

19.

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC).

Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M.

Acta Neuropathol. 2018 Mar;135(3):481-484. doi: 10.1007/s00401-018-1808-0. Epub 2018 Jan 25. No abstract available.

PMID:
29372318
20.

Correction.

Calle S, Louis DN, Westmark R, Westmark K.

J Radiol Case Rep. 2017 Oct 31;11(10):1. doi: 10.3941/jrcr.v11i10.3328. eCollection 2017 Oct.

21.

Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.

DeWitt JC, Jordan JT, Frosch MP, Samore WR, Iafrate AJ, Louis DN, Lennerz JK.

Neuro Oncol. 2017 Nov 29;19(12):1640-1650. doi: 10.1093/neuonc/nox120.

22.

The 2016 WHO classification of central nervous system tumors: what neurologists need to know.

DeWitt JC, Mock A, Louis DN.

Curr Opin Neurol. 2017 Dec;30(6):643-649. doi: 10.1097/WCO.0000000000000490. Review.

PMID:
28901970
23.

Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO… and Shakespeare.

Louis DN, von Deimling A.

Acta Neuropathol. 2017 Oct;134(4):517-520. doi: 10.1007/s00401-017-1765-z. Epub 2017 Aug 11. No abstract available.

PMID:
28801693
24.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

25.

The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions.

Bruner JM, Louis DN, McLendon R, Rosenblum MK, Archambault WT, Most S, Tihan T.

J Neuropathol Exp Neurol. 2017 Mar 1;76(3):189-194. doi: 10.1093/jnen/nlw122.

PMID:
28395084
26.

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.

Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, Escalante LE, Shaw ML, Rodman C, Gillespie SM, Dionne D, Luo CC, Ravichandran H, Mylvaganam R, Mount C, Onozato ML, Nahed BV, Wakimoto H, Curry WT, Iafrate AJ, Rivera MN, Frosch MP, Golub TR, Brastianos PK, Getz G, Patel AP, Monje M, Cahill DP, Rozenblatt-Rosen O, Louis DN, Bernstein BE, Regev A, Suvà ML.

Science. 2017 Mar 31;355(6332). pii: eaai8478. doi: 10.1126/science.aai8478.

27.

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.

Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT Jr, Cahill DP, Barker FG 2nd, Brastianos PK, Santagata S.

Neuro Oncol. 2017 Apr 1;19(4):535-545. doi: 10.1093/neuonc/now235.

28.

cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification.

Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A.

Brain Pathol. 2017 Nov;27(6):851-852. doi: 10.1111/bpa.12457. Epub 2016 Dec 20. No abstract available.

PMID:
27997995
29.

Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.

Chi AS, Cahill DP, Larvie M, Louis DN.

N Engl J Med. 2016 Dec 15;375(24):2381-2389. No abstract available.

PMID:
27974037
30.

Examining Neuropathology: Beginning a Dialogue.

Wiley C, Hart MN, Weidenheim KM, Louis DN, Lee SC.

J Neuropathol Exp Neurol. 2016 Dec;75(12):1179-1183. Review. No abstract available.

PMID:
27941138
31.

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy.

Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A.

Acta Neuropathol. 2017 Jan;133(1):1-3. doi: 10.1007/s00401-016-1646-x. No abstract available.

32.

Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.

Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, Rodman C, Mount C, Filbin MG, Neftel C, Desai N, Nyman J, Izar B, Luo CC, Francis JM, Patel AA, Onozato ML, Riggi N, Livak KJ, Gennert D, Satija R, Nahed BV, Curry WT, Martuza RL, Mylvaganam R, Iafrate AJ, Frosch MP, Golub TR, Rivera MN, Getz G, Rozenblatt-Rosen O, Cahill DP, Monje M, Bernstein BE, Louis DN, Regev A, Suvà ML.

Nature. 2016 Nov 10;539(7628):309-313. doi: 10.1038/nature20123. Epub 2016 Nov 2.

33.

Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS.

J Neurooncol. 2016 Oct;130(1):31-42. Epub 2016 Jul 14.

34.

Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community.

Aldape K, Nejad R, Louis DN, Zadeh G.

Neuro Oncol. 2017 Mar 1;19(3):336-344. doi: 10.1093/neuonc/now181.

35.

Health Care Infrastructure for Financially Sustainable Clinical Genomics.

Lennerz JK, McLaughlin HM, Baron JM, Rasmussen D, Sumbada Shin M, Berners-Lee N, Miller Batten J, Swoboda KJ, Gala MK, Winter HS, Schmahmann JD, Sweetser DA, Boswell M, Pacula M, Stenzinger A, Le LP, Hynes W, Rehm HL, Klibanski A, Black-Schaffer SW, Golden JA, Louis DN, Weiss ST, Iafrate AJ.

J Mol Diagn. 2016 Sep;18(5):697-706. doi: 10.1016/j.jmoldx.2016.04.003. Epub 2016 Jul 25.

36.

The flowering of pathology as a medical discipline in Boston, 1892-c.1950: W.T. Councilman, FB Mallory, JH Wright, SB Wolbach and their descendants.

Louis DN, O'Brien MJ, Young RH.

Mod Pathol. 2016 Sep;29(9):944-61. doi: 10.1038/modpathol.2016.91. Epub 2016 Jun 17. Review.

37.

Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma.

Ho AL, Koch MJ, Tanaka S, Eichler AF, Batchelor TT, Tanboon J, Louis DN, Cahill DP, Chi AS, Curry WT Jr.

J Clin Neurosci. 2016 Sep;31:99-105. doi: 10.1016/j.jocn.2016.02.019. Epub 2016 Jun 6.

PMID:
27279154
38.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW.

Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9. Review.

PMID:
27157931
39.

The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.

Tanboon J, Williams EA, Louis DN.

J Neuropathol Exp Neurol. 2016 Jan;75(1):4-18. Review.

PMID:
26671986
40.

Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.

Cahill DP, Louis DN, Cairncross JG.

CNS Oncol. 2015;4(5):287-94. doi: 10.2217/cns.15.32. Epub 2015 Nov 6. Review.

41.

The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Cahill DP, Sloan AE, Nahed BV, Aldape KD, Louis DN, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):531-49. doi: 10.1007/s11060-015-1909-8. Epub 2015 Nov 3. Review.

PMID:
26530263
42.

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, Sullivan RJ, Frederick DT, Abedalthagafi M, Jones PS, Dunn IF, Nahed BV, Romero JM, Louis DN, Getz G, Cahill DP, Santagata S, Curry WT Jr, Barker FG 2nd.

J Natl Cancer Inst. 2015 Oct 23;108(2). pii: djv310. doi: 10.1093/jnci/djv310. Print 2016 Feb.

43.

BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology.

Shankar GM, Lelic N, Gill CM, Thorner AR, Van Hummelen P, Wisoff JH, Loeffler JS, Brastianos PK, Shin JH, Borges LF, Butler WE, Zagzag D, Brody RI, Duhaime AC, Taylor MD, Hawkins CE, Louis DN, Cahill DP, Curry WT, Meyerson M.

Acta Neuropathol. 2016 Jan;131(1):147-50. No abstract available.

44.

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC.

Cancer Discov. 2015 Nov;5(11):1164-1177. doi: 10.1158/2159-8290.CD-15-0369. Epub 2015 Sep 26.

45.

Rapid Intraoperative Molecular Characterization of Glioma.

Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, Sullivan RJ, Cherniack AD, Garraway LA, Stemmer-Rachamimov A, Reardon DA, Wen PY, Brastianos PK, Curry WT, Barker FG 2nd, Hahn WC, Nahed BV, Ligon KL, Louis DN, Cahill DP, Meyerson M.

JAMA Oncol. 2015 Aug;1(5):662-7. doi: 10.1001/jamaoncol.2015.0917.

46.

Computational Pathology: A Path Ahead.

Louis DN, Feldman M, Carter AB, Dighe AS, Pfeifer JD, Bry L, Almeida JS, Saltz J, Braun J, Tomaszewski JE, Gilbertson JR, Sinard JH, Gerber GK, Galli SJ, Golden JA, Becich MJ.

Arch Pathol Lab Med. 2016 Jan;140(1):41-50. doi: 10.5858/arpa.2015-0093-SA. Epub 2015 Jun 22.

47.

Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.

Nigim F, Cavanaugh J, Patel AP, Curry WT Jr, Esaki S, Kasper EM, Chi AS, Louis DN, Martuza RL, Rabkin SD, Wakimoto H.

J Neuropathol Exp Neurol. 2015 Jul;74(7):710-22. doi: 10.1097/NEN.0000000000000210.

48.

Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011.

Lym RL, Ostrom QT, Kruchko C, Couce M, Brat DJ, Louis DN, Barnholtz-Sloan JS.

J Neurooncol. 2015 May;123(1):43-51. doi: 10.1007/s11060-015-1775-4. Epub 2015 Apr 12.

49.

Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.

Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis JM, Abedalthagafi M, Borges LF, Coumans JV, Curry WT, Nahed BV, Shin JH, Paek SH, Park SH, Stewart C, Lawrence MS, Cibulskis K, Thorner AR, Van Hummelen P, Stemmer-Rachamimov AO, Batchelor TT, Carter SL, Hoang MP, Santagata S, Louis DN, Barker FG, Meyerson M, Getz G, Brastianos PK, Cahill DP.

Acta Neuropathol Commun. 2014 Dec 24;2:167. doi: 10.1186/s40478-014-0167-x.

50.

Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia.

Jones RT, Abedalthagafi MS, Brahmandam M, Greenfield EA, Hoang MP, Louis DN, Hornick JL, Santagata S.

Mod Pathol. 2015 Apr;28(4):596-606. doi: 10.1038/modpathol.2014.150. Epub 2014 Nov 21.

Supplemental Content

Loading ...
Support Center